A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19

NCT04605926 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor has currently elected to withhold study initiation

Conditions

Coronavirus

Interventions

BIOLOGICAL: EQ001
BIOLOGICAL: EQ001 Placebo

Sponsor

Biocon Limited